First Trust Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.66M | Sell |
184,386
-3,159,482
| -94% | -$69.5M | ﹤0.01% | 1639 |
|
|
2026
Q1 | $74.4M | Buy |
3,343,868
+1,073,834
| +47% | +$25.7M | 0.05% | 436 |
|
|
2025
Q4 | $60.6M | Buy |
2,270,034
+326,882
| +17% | +$7.81M | 0.04% | 488 |
|
|
2025
Q3 | $41.5M | Sell |
1,943,152
-491,224
| -20% | -$11.6M | 0.03% | 650 |
|
|
2025
Q2 | $52.5M | Buy |
2,434,376
+65,914
| +3% | +$1.23M | 0.04% | 519 |
|
|
2025
Q1 | $39.3M | Sell |
2,368,462
-331,663
| -12% | -$6.03M | 0.03% | 643 |
|
|
2024
Q4 | $49.5M | Buy |
2,700,125
+574,251
| +27% | +$9.27M | 0.04% | 514 |
|
|
2024
Q3 | $32.7M | Buy |
2,125,874
+57,554
| +3% | +$960K | 0.03% | 637 |
|
|
2024
Q2 | $33.6M | Buy |
2,068,320
+419,522
| +25% | +$6.77M | 0.03% | 613 |
|
|
2024
Q1 | $30.5M | Sell |
1,648,798
-128,509
| -7% | -$3.18M | 0.03% | 638 |
|
|
2023
Q4 | $55.6M | Buy |
1,777,307
+148,526
| +9% | +$3.55M | 0.06% | 407 |
|
|
2023
Q3 | $33.9M | Sell |
1,628,781
-875,664
| -35% | -$23.8M | 0.04% | 518 |
|
|
2023
Q2 | $60M | Sell |
2,504,445
-210,040
| -8% | -$4.67M | 0.07% | 401 |
|
|
2023
Q1 | $51.1M | Sell |
2,714,485
-167,876
| -6% | -$3.2M | 0.06% | 437 |
|
|
2022
Q4 | $45.9M | Sell |
2,882,361
-37,499
| -1% | -$586K | 0.05% | 467 |
|
|
2022
Q3 | $47.8M | Buy |
2,919,860
+748,618
| +34% | +$12.1M | 0.06% | 442 |
|
|
2022
Q2 | $30.6M | Sell |
2,171,242
-160,912
| -7% | -$3M | 0.04% | 559 |
|
|
2022
Q1 | $56.5M | Sell |
2,332,154
-1,020,729
| -30% | -$24.7M | 0.06% | 476 |
|
|
2021
Q4 | $78.3M | Buy |
3,352,883
+750,420
| +29% | +$15.1M | 0.08% | 322 |
|
|
2021
Q3 | $43.2M | Sell |
2,602,463
-322,174
| -11% | -$6.21M | 0.05% | 499 |
|
|
2021
Q2 | $71.3M | Buy |
2,924,637
+1,347,516
| +85% | +$30.4M | 0.08% | 352 |
|
|
2021
Q1 | $40.7M | Sell |
1,577,121
-45,455
| -3% | -$2M | 0.05% | 481 |
|
|
2020
Q4 | $86.7M | Sell |
1,622,576
-94,555
| -6% | -$4.69M | 0.11% | 217 |
|
|
2020
Q3 | $70.8M | Buy |
1,717,131
+296,883
| +21% | +$12.8M | 0.11% | 224 |
|
|
2020
Q2 | $68.8M | Sell |
1,420,248
-16,101
| -1% | -$773K | 0.12% | 210 |
|
|
2020
Q1 | $60.7M | Buy |
1,436,349
+7,889
| +0.6% | +$325K | 0.14% | 205 |
|
|
2019
Q4 | $61.1M | Sell |
1,428,460
-1,101,903
| -44% | -$47.9M | 0.1% | 278 |
|
|
2019
Q3 | $91.1M | Sell |
2,530,363
-1,688,706
| -40% | -$51.2M | 0.17% | 139 |
|
|
2019
Q2 | $113M | Sell |
4,219,069
-596,707
| -12% | -$15.2M | 0.21% | 102 |
|
|
2019
Q1 | $129M | Buy |
4,815,776
+677,051
| +16% | +$15.8M | 0.26% | 76 |
|
|
2018
Q4 | $66.9M | Sell |
4,138,725
-1,731,968
| -30% | -$33.6M | 0.16% | 145 |
|
|
2018
Q3 | $122M | Buy |
5,870,693
+3,267,247
| +125% | +$51.4M | 0.23% | 84 |
|
|
2018
Q2 | $39.8M | Buy |
2,603,446
+840,425
| +48% | +$15M | 0.08% | 284 |
|
|
2018
Q1 | $39.6M | Buy |
1,763,021
+239,909
| +16% | +$6.64M | 0.09% | 259 |
|
|
2017
Q4 | $45.9M | Buy |
1,523,112
+312,671
| +26% | +$10M | 0.11% | 216 |
|
|
2017
Q3 | $45.6M | Sell |
1,210,441
-191,588
| -14% | -$6.23M | 0.12% | 189 |
|
|
2017
Q2 | $39.1M | Buy |
1,402,029
+530,103
| +61% | +$15.8M | 0.1% | 223 |
|
|
2017
Q1 | $30M | Sell |
871,926
-200,532
| -19% | -$7.08M | 0.08% | 301 |
|
|
2016
Q4 | $30.9M | Buy |
1,072,458
+249,922
| +30% | +$6.61M | 0.09% | 265 |
|
|
2016
Q3 | $26.2M | Sell |
822,536
-33,788
| -4% | -$1.15M | 0.08% | 337 |
|
|
2016
Q2 | $27.8M | Buy |
+856,324
| New | +$28.7M | 0.09% | 283 |
|
Other funds holding ACAD
BBA
RI
PAI
First Trust Advisors's ACAD Position: Q2 2026 in Review
First Trust Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 94% in Q2 2026, selling an estimated $69.5M and leaving 184,386 shares worth $4.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1639.
First Trust Advisors first reported a position in ACAD in Q2 2016 and has held it in 41 quarters since. The position peaked at $129M in Q1 2019. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- First Trust Advisors held 184,386 shares of Acadia Pharmaceuticals worth $4.66M as of Q2 2026.
- First Trust Advisors sold 3,159,482 Acadia Pharmaceuticals shares in Q2 2026, an estimated $69.5M.
- Acadia Pharmaceuticals made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1639 holding.
- First Trust Advisors first reported a position in Acadia Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
- First Trust Advisors's Acadia Pharmaceuticals position peaked at $129M in Q1 2019.
- 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.